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Genotypes and allelic frequencies of TPH2, 5-HTTLPR, the 5-HTT (SLC6A4) intron 2 variable-number tandem repeat (VNTR) region, and the
MAOAVNTR region were determined in brain-stem samples of 20 “genuine” SIDS cases and compared with results obtained from 150 healthy
controls. The SNP G1463A responsible for 80% functionality loss of TPH2 (tryptophan hydroxylase 2) was not detected, neither in SIDS infants
nor in the controls. In contrast, a strict relation was found between the 5-HTTLPR genotype and its allelic frequencies with SIDS cases. The L/L
genotype and the long allele (L) of the promoter region of the serotonin transporter were significantly associated (likelihood ratio (LR) test,
pb0.001) with the syndrome (L/L, 60% SIDS vs 14% controls; L, 80% SIDS vs 42.6% controls). Polymorphisms of the intron 2 VNTR of
the same gene showed a trend for significant differences between genotypes 10/10 and 12/12 (LR test, p=0.068), with the L-12 haplotype being
almost twofold in SIDS (44.5%) with respect to controls (23.4%). Differences were even higher considering the genotype combination L/L-12/12
(20% SIDS vs 2.6%), and variations among categories were statistically highly significant (pb0.001). Although additional differences were
observed in the frequency of the MAOA (monoamine oxidase A) VNTR genotype 3R/3R between SIDS and controls (respectively 15% vs 26%),
the results were not supported by statistical significance. Molecular polymorphisms are discussed considering their functional role in regulating
serotonin synthesis (TPH2), neuronal reuptake (5-HTTLPR and 5-HTT intron 2), and catabolism (MAOA) in the nervous system of Italian SIDS
infants. Comparisons are made with previous data obtained in different ethnic groups.
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death of an infant, within 1 year of age, that is unexpected by
history and for which a full postmortem examination, including
in-depth examination of the autonomic nervous system, fails to
demonstrate a possible cause of death [1]. Excluding the neonatal
period, the syndrome is the most common cause of infant death
in developed countries. The incidence of SIDS in Italy is about
0.70/1000 live births each year but only a marginal number of
these deaths are diagnosed and fully investigated (the number of
live birthswas 562,600 in 2004 (www.populationeurope.org) and
about 400 deaths probably occurred that year). To fulfill diag-⁎ Corresponding author. Fax: +39 0521 905657.
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doi:10.1016/j.ygeno.2008.01.010nostic and scientific gaps, the Italian national government has
recently passed a law (No. 31; February 2, 2006) with the aim of
increasing necroscopic investigations and acquiring additional
scientific knowledge on this syndrome. As a matter of
comparison, the SIDS incidence rate in the United States was
in the range 0.67–0.80/1000 births in the same period [2,3] and
was much lower in Japan, with 0.24/1000 births [4].
Although SIDS has been known since ancient times (Bible, 1
Kings, chapter 3,19), its etiopathogenesis mechanisms are still
obscure. A possible contribution of genetic factors has long been
denied but recent advances in molecular genetics have opened
new perspectives in the definition of pathogenic mechanisms of
SIDS. Since the first studies on genes involved in metabolic
disorders occasionally responsible for unexpected perinatal
486 F. Nonnis Marzano et al. / Genomics 91 (2008) 485–491deaths [5], additional associations between DNA markers, risk
factors, and SIDS have been demonstrated [6–10]. In addition, a
population genetic component also emerges when analyzing the
SIDS incidence in different ethnic groups [11] and particularly the
relevant values of small bottlenecked populations such as the
Native Americans and the Maori [12,13].
Among the variety of genes investigated during the past
decade, several studies have identified polymorphisms in the
serotonin transporter (5-HTT) (SLC6A4 encoding 5-HTT) as a
predisposing factor in infant death [9,14]. A notable finding was
the increased frequency of the long allele (L) of the promoter
region of the gene in specific populations, consistent with the
patterns of SIDS prevalence in the different ethnic groups. Narita
et al. [15] identified an association between the long allele of 5-
HTT and SIDS in a small Japanese cohort. Weese-Mayer et al.
[16] confirmed this association in a larger sample of American
SIDS cases. Furthermore, an association between SIDS and the L-
12 haplotype (“long” promoter allele and “12” allele of intron 2 of
the same gene) was found in the African-American population
[17]. The ethnic disparity observed within the American
population was recently confirmed by the detection of rare
mutations occurring in the FEV gene expressed in central 5-HT
neurons [18]. To understand whether serotonin is the real key
factor in SIDS, Weese-Mayer et al. [9] have recently emphasized
the need to assess allelic frequencies of the 5-HTT promoter
region and the intron 2 variable-number tandem repeat (VNTR)
region in several countries to obtain a broader view of the role ofFig. 1. General model of serotonin synthesis, release regulation, reuptake, and metab
and 5-HTT are nuclear-encoded proteins that work at the cytoplasmic (TPH-2), mitoc
on their function.the serotonin transporter in different SIDS populations and its
correlation with phenotypic characters. Since the distribution of
5-HTT alleles and genotypes varies among subjects of different
ethnicities, the degree of association of the polymorphisms with
SIDS may also be different.
Considering the functional involvement of serotonin in SIDS
and the recent evidence of multiple serotoninergic brain-stem
abnormalities in the syndrome [2,19], which may be linked to
additional genes regulating the neurotransmission pathway, we
carried out an investigation to define the involvement of three
genes influencing serotonin metabolism in both the autonomic
and the central nervous systems (Fig. 1). Polymorphisms of
two different 5-HTT regions (5-HTTLPR, hydroxytryptamine
transporter-linked polymorphic region, and Stin2, intron 2
VNTR), the promoter region ofMAOA (monoamine oxidase A),
and TPH2 (tryptophan hydroxylase 2) were investigated in an
Italian SIDS population and controls. The serotonin 3′ UTR
single-nucleotide polymorphism (SNP) was not considered in
this work since a recent investigation demonstrated that this
polymorphism does not influence the SIDS risk [20].With respect
to previous papers dealing with serotonin involvement in SIDS,
this is the first investigation considering two additional genes
influencing the 5-HTT action in the neurotransmission pathway.
In fact, monoamine oxidase A is a mitochondrial enzyme that
regulates serotoninergic signals through catabolism of vesicular
serotonin in the presynaptic region, while TPH-2 regulates the
first step of serotonin synthesis inside the presynaptic neuronolism in a presynaptic neuron (modified from Ferrari et al. [35]). TPH-2, MAO,
hondrial (MAO), and cell membrane (5-HTT) levels. See text for further details
Table 2
Genotype and haplotype frequencies determined for the combined promoter
variant and the intron 2 VNTR of the 5-HTT locus




LR test p value
n % n %
Genotype 120.10 b0.001
S/S 10/10 0 0.0 0 0.0
S/S 10/12 13 8.7 0 0.0
S/S 12/12 30 20.0 0 0.0
L/S 10/10 17 11.3 0 0.0
L/S 10/12 43 28.7 7 35.0
L/S 12/12 26 17.4 1 5.0
L/L 10/10 4 2.6 0 0.0
L/L 10/12 13 8.7 8 40.0
L/L 12/12 4 2.6 4 20.0
Haplotype 288.30 b0.001
S 10 73 18.9 7 12.9
S 12 142 36.8 8 14.9
L 10 81 20.9 15 27.7
L 12 90 23.4 24 44.5
487F. Nonnis Marzano et al. / Genomics 91 (2008) 485–491(Fig. 1). An upstream variable number of tandem repeats within
the MAOA promoter region (MAOA-u VNTR) was related to the
transcriptional efficiency of the gene [21], while Zhang et al. [22]
identified a missense mutation (G1463A) that causes about 80%
of function loss in the neuronal-specific TPH2, which could have
significant physiological consequences for brain serotonin
synthesis.
Genotypes and allelic frequencies of 5-HTTLPR, intron 2
VNTR, MAOA-u VNTR, and TPH2 were therefore determined
in 20 SIDS cases and compared with data obtained in 150
healthy controls. Infants were also genotyped for mutations
carried by SCN5A to exclude the long-QT syndrome [23] (data
not shown). Genetic results are discussed with respect to a
possible serotonin pathway in the nervous system of SIDS in-
fants also considering possible population or ethnicity differ-
ences. Emphasis has been put on the functional role of the
different polymorphisms in regulating serotonin synthesis
(TPH2), neuronal reuptake (5-HTTLPR and 5-HTT intron 2),
and catabolism (MAOA) in the brain stem.
Results
TPH2—tryptophan hydroxylase 2
The SNP G1463A responsible for the R441H mutation was
investigated by sequence analysis of 720 bp of exon XI. Within
this DNA region, 650-bp amplicons were compared between 20
SIDS infants and 50 controls. No polymorphisms were found
and 100% identity resulted between pathologic and nonpatho-
logic samples. The G1463A SNP was not detected in any of the
pathologic samples nor in the controls.
5-HTT—serotonin transporter
Two different regions of serotonin transporter were inves-
tigated: the so-called 5-HTT-linked polymorphic region of theTable 1
Frequencies of 5-HTT genotypes and alleles of the promoter region (5-HTTLPR)
and intron 2 determined in SIDS infants and controls
Controls (n=150) SIDS (n=20) LR test p value
n % n %
5-HTTLPR
Genotype 10.39 0.001
L/L 21 14.0 12 60.0
L/S 86 57.3 8 40.0
S/S 43 28.7 0 0.0
Allele 12.36 b0.001
L 129 42.6 32 80.0
S 171 57.4 8 20.0
Intron 2-VNTR
Genotype 3.33 0.068
10/10 21 14.0 0 0.0
10/12 69 46.0 15 75.0
12/12 60 40.0 5 25.0
Allele 0.002 0.964
10 111 37.0 15 37.5
12 189 63.0 25 62.5promoter and VNTR polymorphisms of intron 2. Frequencies of
genotypic and allelic data for both gene regions are reported in
Table 1.
Both short (S) and L alleles of the promoter region were
found. In particular, 12 homozygote genotypes, L/L, and 8 he-
terozygotes, S/L, were detected in the 20 investigated SIDS
infants. The frequency of the L/L genotype was much higher in
SIDS cases (60%) than in the controls (14%), while the fre-
quency of the S/L genotype was similar in the two groups (40%
vs 57.3%). Interestingly, no infant affected by the syndrome had
the S/S genotype (0% SIDS vs 28.7% controls). The statistical
significance of overall genotype differences between SIDS and
controls was defined by LR2df=10.39 (p=0.001). Considering
allelic frequencies, the L allele was 80% in SIDS infants and
42.6% in the controls (LR1df=12.36, pb0.001).
Polymorphisms of the VNTR of intron 2 are also important
due to their functional role in gene expression. According to
Weese-Mayer et al. [17] the frequencies of the 12/12 genotype
and 12 allele should be significantly different between African-
American and Caucasian cases. Genotypes 10/12 and 12/12
were detected in Italian SIDS infants. No infant with genotype
10/10 emerged from among 20 investigated cases. From a sta-
tistical point of view, Stin2 polymorphisms showed a trend of
significant differences between genotypes 10/10+10/12 and 12/
12 (LR1df=3.33, p=0.068). This tendency seemed influenced
by the limited number of African-Italian SIDS in our dataset.
Real differences between ethnicities within the Italian popula-
tion could not be assessed since our SIDS cohort was con-
stituted by 19 Caucasian subjects and only 1 African Italian. It
must be remarked that this last case was L/L and 12/12, the
combined genotypes associated with increased SIDS death in
the African-American population [17]. Although genotype dif-
ferences were observed between SIDS cases and matched
controls, the frequencies of the 10 and 12 alleles were exactly
the same in the two groups.
Table 3
Frequencies of MAOA-u VNTR genotypes and alleles determined in SIDS
infants and controls
MAOA Controls (n=150) SIDS (n=20) LR test p value
n % n %
Genotype 0.720 0.396
3/3 39 26.0 3 15.0
3/3.5 0 0.0 0 0.0
3/4 43 28.7 6 30.0
3/5 0 0.0 0 0.0
3.5/3.5 0 0.0 0 0.0
3.5/4 4 2.6 1 5.0
3.5/5 0 0.0 0 0.0
4/4 64 42.7 10 50.0
4/5 0 0.0 0 0.0
5/5 0 0.0 0 0.0
Allele 0.805 0.370
3 121 40.3 12 30.0
3.5 4 1.3 1 2.5
4 175 58.4 27 67.5
5 0 0.0 0 0.0
488 F. Nonnis Marzano et al. / Genomics 91 (2008) 485–491A combined analysis of the 5-HTT promoter and intron 2
variants was also performed for the total dataset considering the
previously defined significant linkage disequilibrium of the two
gene regions [17]. The haplotype analysis demonstrated that the
L-12 haplotype was almost twofold in SIDS (44.5%) with respect
to matched controls (23.4%). Differences were even higher
considering genotype combinations L/L-10/12 (40% SIDS vs
8.7% controls) and L/L-12/12 (20% SIDS vs 2.6% controls).
Comparisons among categories resulted in highly significant
differences (pb0.001) for both genotype and haplotype combina-
tions. Data for promoter and Stin2 combinations are presented in
Table 2.
MAOA—monoamine oxidase A
Three variants of the MAOA-u VNTR polymorphism were
detected within the promoter region. Alleles defined by 3
(320 bp), 3.5 (335 bp), and 4 (350 bp) repeats consistent with
allelic nomenclature [24] were identified in 20 SIDS samples
and the 150 controls. Alleles 2.5R and 5R were not noticed.
Data on genotype and allele frequencies of MAOA are re-
ported in Table 3. The frequency of genotype 3R/3R was higher
in the controls (26%) with respect to SIDS infants (15%). Some
difference also emerged for genotype 3.5R/4R even though
this genotype was scarcely represented in our investigation
(2.6–5.0%). Genotypes 3R/4R and 4R/4R showed only
marginal differences. Considering allelic frequencies, VNTR-
3 was lower in SIDS (30.0%) than the controls (40.3%).
Despite differences in the genotype distribution and allelic
frequencies between SIDS and controls, no statistical signifi-
cance emerged for this gene (p values in the range 0.37–0.39).
Discussion
Although the serotoninergic system is complex, the serotonin
transporter (5-HTT) is a major determinant of serotoninergicfunction through modification of gene transcription and tran-
sporter expression [20,25,26]. As a genetic factor, the poly-
morphisms of 5-HTT appear important for the etiology of SIDS
[9]. Two common polymorphisms of this gene have been iden-
tified, a 44-bp insertion/deletion polymorphism in the upstream
regulatory region (5-HTTLPR) and a VNTR polymorphism in
the second intron (Stin2) [25]. In the promoter region it was
demonstrated that two allelic variants (S and L) differentially
modulate transcription of the 5-HTT gene, with the L variant
being more efficient [25]; as well, it has been suggested that
the VNTR region may act as a transcriptional regulator with the
12-repeat allele having stronger enhancer-like properties than
the 10-repeat allele [26]. In this study the frequency of the L/L
genotype was over fourfold higher in SIDS infants than in
controls (60 vs 14%). Considering allelic frequencies, the L
allele was twofold higher in SIDS infants with respect to controls
(80 vs 42.6%). Comparisons between pathologic and nonpatho-
logic samples reached high statistical significance at both the
genotype (p=0.001) and the allelic level (pb0.001). Interest-
ingly, no SIDS infants with the S/S genotype were observed
among our 20 investigated cases. Genotype and allele distribu-
tions for intron 2 did not differ significantly between SIDS and
controls over the entire dataset. Although a statistical trend
(p=0.068) was observed in the genotype distribution, the oc-
currence of the 12/12 genotype was lower in pathologic samples
than controls. The frequencies of the 10 and 12 alleles were
exactly the same in the two groups. Despite this, a significant
association emerged between SIDS and the combined genotypes
L/L-10/12 and L/L-12/12 with respect to controls (pb0.001).
In addition, a haplotype analysis performed considering both
5-HTTLPR and intron 2 VNTR alleles demonstrated that the
L-12 haplotype was associated with increased SIDS risk. In
fact, the haplotype percentage was almost twofold in our SIDS
cases (44.5%) with respect to matched controls (23.4%). A
major contribution to the association was due mainly to the L
allele (pb0.001).
Despite the ethnic variability in the 5-HTT promoter poly-
morphisms data [27] that might provide insight into the
remarkable disparities in SIDS incidence in different popula-
tions, it is interesting to observe that our results are in agreement
with previously published data in the Japanese [15] and Ame-
rican [16] SIDS populations. In fact, Narita et al. [15] observed
an L/L genotype frequency of 18.5% (Japanese SIDS) vs 2.6%
(Japanese controls), while Weese-Mayer et al. [16,17] found
40.9% in SIDS vs 27.3% in controls considering the Caucasian
population of North America. Similar to Narita et al. [15] and
Weese-Mayer et al. [16], the L allele frequency was twice in our
SIDS population with respect to controls. These data are an
important confirmation of previous considerations by Weese-
Mayer et al. [9,16] stating that, despite ethnic variation in the
frequency of the L allele, SIDS cases were more likely than
controls to have the long allele. As concerns intron 2, although
genotype and allele distribution did not differ significantly
between SIDS and controls, the results were in agreement with
the only previously published data by Weese-Mayer et al. [17]
that found no differences between SIDS and controls in the
Caucasian population but did find differences in the African-
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between ethnicities since our SIDS dataset was composed of
19 Caucasian subjects and only 1 African Italian. Interestingly,
this African infant belonged to genotype 12/12. Considering a
major contribution of the L allele, the haplotype analysis
performed considering both 5-HTTLPR and Stin2 alleles de-
monstrated that the L-12 haplotype showed increased SIDS risk
in the Italian population as much as in the North American
group [17].
Two additional genes were investigated to address synergic
interactions within the neuronal transmission. In particular,
tryptophan hydroxylase (TPH-1 and TPH-2) is the rate-limiting
enzyme in 5-HT synthesis and in contrast to TPH1, which con-
trols most peripheral 5-HT synthesis, TPH2 was recently found
to be neuronal specific and predominantly expressed in brain
serotoninergic neurons originating from raphe nuclei [28]. In
this work we investigated an SNP in human TPH2 that results in
80% loss of function in serotonin production [22]. Neither the
SNP G1463A responsible for the R441H mutation nor ad-
ditional polymorphisms were detected in SIDS infants and
healthy controls, confirming the highly conserved sequence of
the gene. Considering the low recurrence of this point muta-
tion in the population [22], a possible role for TPH2 in the
syndrome pathogenesis could therefore be only occasional. To
complete the serotonin pathway, an upstream VNTR within the
MAOA promoter region [24] was also investigated. It consists of
a 30-bp repeat sequence consisting of 3, 3.5, 4, or 5 copies, and
expression studies indicate that the number of repeats is related
to the transcriptional efficiency of the gene, such that the three-
repeat allele is associated with reduced gene expression and,
hence, reduced activity, relative to the other alleles [21,29]. In
this investigation, a difference of genotype 3R/3R distribution
between SIDS and controls was observed. Although with low
frequencies, the genotype value was higher in the healthy con-
trols (26%) than in SIDS infants (15%) but results did not reach
statistical significance. With respect to previously published
data obtained in healthy individuals belonging to different eth-
nic groups, our results are in strict agreement with those of
Deckert et al. [30]. In Deckert's paper the frequency of alleles
3R and 4R determined in the general Italian population was
exactly the same as in our investigated control cohort. There-
fore, it can be hypothesized that the observed differences in
allele 3R between SIDS cases and controls are real and could
play a certain role in the syndrome pathogenesis. Unfortunately,
one of the main limitations of this result is the limited SIDS
sample size. It must also be remarked this is the first report on
the MAOA-u VNTR polymorphism in a cohort of SIDS infants
and functional considerations will have to be assessed further in
a larger sample.
In conclusion, this paper highlights the importance of genetic
studies to define etiopathogenesis mechanisms of SIDS and
points out the role of the serotonin transporter by confirming the
involvement of 5-HTT polymorphisms in the Italian SIDS po-
pulation. The consistent finding of this genetic investigation in a
country different than those previously investigated provides
additional knowledge for a better understanding of ethnic dis-
parities and SIDS.Materials and methods
Twenty SIDS victims (10 females and 10 males), 2 days to 7 months of age,
were selected for this study after a complete postmortem investigation
performed according to pathologic and forensic criteria [31]. It is noteworthy
that 17 infants died within the third month of age, while only 3 passed between 5
and 7 months of age. Brain-stem tissues of SIDS victims were sectioned at the
level of the arcuate nucleus (medulla oblongata) and conserved as either fresh
ethanol-fixed or paraffin-embedded tissues. In addition, whole blood or urine
samples were obtained from 150 healthy subjects (80 females and 70 males)
older than 1 year to be used as controls.
Genomic DNA was extracted from autoptic fresh tissues using the Aqua
Pure Genomic DNA Kit (Bio-Rad Laboratories) following the producer's
instructions. Paraffined tissues were heated and treated with xylol to eliminate
paraffin, according to the optimized protocol proposed by Shi et al. [32]. In
particular, deparaffination was carried out on five slices of 10-µm thickness
obtained from each paraffin block. After deparaffination, DNA was extracted
and purified using a standard proteinase K/SDS–phenol/chloroform method
[33]. Extraction yield ranged approximately from 1000 to 10,000 ng. The use of
fresh (frozen) tissue is certainly recommended since extraction from paraffin-
embedded samples was not always successful. In fact, 10 samples were dis-
charged after DNA extraction and only 4 were suitable for DNA amplification.
DNAwas extracted from 200 µl of whole-blood samples of healthy controls
using the Charge Switch gDNA Blood Kit (Invitrogen). Urine samples were
used to avoid blood collection from children [34]. About 100 ml of first morning
urine was collected and centrifuged at 15,000 rpm. Sedimented cells were then
pipetted and submitted to DNA extraction carried out by means of a QIAmp
DNA Blood Mini Kit (Qiagen).
Amplification reactions and conditions were the following: TPH2 was
amplified by PCR (thermal cycler MJ Research PTC100) to detect the G1463A
polymorphism using primers reported by Zhang et al. [22]: forward, 5′-
ATGCCTTATCACCACCTTCC-3′, and reverse, 5′-TTAGATCTGAAAAA-
GAAAAGGGC-3′). The first PCR was performed in a total volume of 25 µl
containing 30 ng of genomic DNA, 0.2 mM dNTPs, 10 pmol of forward and
reverse primers, 1× reaction buffer, 1.5 mM Mg2+, and 1 U of GoTaq DNA
polymerase (Promega, Madison, WI, USA). PCR conditions were developed in
a touchdown reaction consisting of 3 cycles at annealing temperature, 52, 50,
and 48 °C followed by 30 cycles at 50 °C. PCR products of 720 bp were purified
and genotyped by both forward and reverse sequencing. Gel band purification
was performed using the GFX PCR DNA Kit (Amersham Biosciences), while
sequencing PCR was carried out using the CEQ DTCS-Quick Start Kit (Beck-
man Coulter), and products were loaded on a CEQ 8000 automatic sequencer
(Beckman Coulter). Nucleotide sequences were compared to those available in
genomic databases using BLAST and FASTA. Multiple alignments of sense and
antisense sequences were conducted using the softwares CLUSTALX,
Sequencher, and Genedoc.
MAOA-u VNTR was typed using primers suggested by Cohen et al. [29]:
forward, 5′-ACAGCCTGACCGTGGAGAAG-3′, and reverse, 5′-GAACG-
GACGCTCCATTCGGA-3′. The size of the amplified fragment is 350 bp for
alleles with four copies of repeats. PCR amplification was conducted in a final
volume of 25 µl consisting of 30 ng of genomic DNA, 0.2 mM dNTPs, 10 pmol
of forward and reverse primers, 1× reaction buffer, 1.5 mM Mg2+, and 1 U of
GoTaq DNA polymerase (Promega). Cycling conditions were 5 min at 95 °C for
initial denaturation; followed by 40 cycles of 1 min at 95 °C, 1 min at 65 °C, and
1 min at 72 °C; and a final extension at 72 °C for 10 min. PCR products were
separated by 2.5% agarose gel electrophoresis followed by ethidium bromide
staining and visualized under UV light. The various alleles were determined
using the GeneRuler 100 bp DNA ladder (Fermentas, Hanover, MD, USA).
Polymorphisms of the serotonin transporter 5-HTT were investigated using
specific primers for 5-HTTLPR and intron 2 VNTR. According to Gelernter et al.
[27], they were, respectively, forward, 5′-ATGCCAGCACCTAACCCCTA-
ATGT-3′, and reverse, 5′-GGACCGCAAGGTGGGCGGGA-3′, for 5-HTTLPR
and forward, 5′-GTCAGTATCACAGGCTGCGAG-3′, and reverse, 5′-TGTTC-
CTAGTCTTACGCCAGTG-3′, for intron 2.
PCR amplification was performed in a final volume of 20 µl consisting of
30 ng of genomic DNA, 0.2 mM dNTPs, 10 pmol of forward and reverse
primers, 1.5 mM Mg2+, 1× reaction buffer, and 1 U of GoTaq DNA polymerase
(Promega). Amplification conditions for 5-HTTLPR were an initial step of
490 F. Nonnis Marzano et al. / Genomics 91 (2008) 485–491denaturation at 94 °C for 10 min and subsequently 35 cycles comprising 1 min at
94 °C, 1 min at 66 °C, and 1 min at 72 °C. For the intron 2 polymorphism the
annealing temperature was reduced to 56 °C. Different alleles were separated on
agarose gel electrophoresis following the same procedure previously reported
for MAOA.
To investigate possible associations between genotypes/alleles and experi-
mental groups, a likelihood ratio χ2 test was performed. It is a more robust test
than the classical Pearson χ2 to deal with low-number categories such as
genotype and allele groups. Statistical analyses were performed using Statistica
software (version 7.1). p values were considered highly significant when lower
than 0.01 and significant in the range 0.01bpb0.05. In addition, values in the
range 0.05bpb0.10 were considered a trend of significance. Degrees of
freedom were equal to 1 less than the number of alleles/genotypes.
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